Floatz logo

CLOPIDOGREL

Atherosclerosis

Ewha Womans University Seoul HospitalSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Atherosclerosis cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
SIMVASTATIN
Northern California Institute of Research and Education
Phase 4BBB
ADVICOR COMPONENT NIACIN
University of Washington
Phase 4BB
ATORVASTATIN
Erasmus Medical Center
Phase 4BB
Ezetimibe
paresh Dandona
Phase 4BB

View all 45 →

Same molecule, other indications

CLOPIDOGREL is also rated in:

myocardial infarctionActive
A
Indicative · Phase 4
81 / 100
View asset →
transient ischemic attackActive
BBB
Indicative · Phase 4
77 / 100
View asset →
peripheral arterial diseaseActive
BBB
Indicative · Phase 4
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →